DNA damage, p53, apoptosis and vascular disease

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 621, Issue 1-2, 2007, Pages 75-86

  Mercer, John ^a   Mahmoudi, Melli ^a   Bennett, Martin ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

APOPTOSIS; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CAUSE OF DEATH; CELL TYPE; DNA DAMAGE; HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR DISEASE;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; DNA DAMAGE; ENDOTHELIUM, VASCULAR; HUMANS; OXIDATIVE STRESS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR DISEASES;

EID: 34447258120     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mrfmmm.2007.02.011     Document Type: Article

References (98)

1. Gu L., Okada Y., Clinton S.K., Gerard C., Sukhova G.K., Libby P., and Rollins B.J. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol. Cell 2 (1998) 275-281
2. Boring L., Gosling J., Cleary M., and Charo I.F. Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature 394 (1998) 894-897
3. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
4. Geng Y., and Libby P. Evidence for apoptosis in advanced human atheroma: colocalization with interleukin-1β converting enzyme. Am. J. Pathol. 147 (1995) 251-266
5. Isner J., Kearney M., Bortman S., and Passeri J. Apoptosis in human atherosclerosis and restenosis. Circulation 91 (1995) 2703-2711
6. Bennett M., Evan G., and Schwartz S. Apoptosis of human vascular smooth muscle cells derived from normal vessels and coronary atherosclerotic plaques. J. Clin. Invest. 95 (1995) 2266-2274
7. Lutgens E., de Muinck E., Kitslaar P., Tordoir J., Wellens H., and Daemen M. Biphasic pattern of cell turnover characterizes the progression from fatty streaks to ruptured human atherosclerotic plaques. Cardiovasc. Res. 41 (1999) 473-479
8. Durand E., Scoazec A., Lafont A., Boddaert J., Al Hajzen A., Addad F., Mirshahi M., Desnos M., Tedgui A., and Mallat Z. In vivo induction of endothelial apoptosis leads to vessel thrombosis and endothelial denudation: a clue to the understanding of the mechanisms of thrombotic plaque erosion. Circulation 109 (2004) 2503-2506
9. Bennett M.R. Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc. Res. 41 (1999) 361-368
10. Bauriedel G., Hutter R., Welsch U., Bach R., Sievert H., and Luderitz B. Role of smooth muscle cell death in advanced coronary primary lesions: implications for plaque instability. Cardiovasc. Res. 41 (1999) 480-488
11. von der Thusen J.H., van Vlijmen B.J., Hoeben R.C., Kockx M.M., Havekes L.M., van Berkel T.J., and Biessen E.A. Induction of atherosclerotic plaque rupture in apolipoprotein E-/- mice after adenovirus-mediated transfer of p53. Circulation 105 (2002) 2064-2070
12. Boyle J.J. Macrophage activation in atherosclerosis: pathogenesis and pharmacology of plaque rupture. Curr. Vasc. Pharmacol. 3 (2005) 63-68
13. Matter C.M., Chadjichristos C.E., Meier P., von Lukowicz T., Lohmann C., Schuler P.K., Zhang D., Odermatt B., Hofmann E., Brunner T., Kwak B.R., and Luscher T.F. Role of endogenous Fas (CD95/Apo-1) ligand in balloon-induced apoptosis, inflammation, and neointima formation. Circulation 113 (2006) 1879-1887
14. Boyle J., Bowyer D., Weissberg P., and Bennett M. Human blood derived macrophages induce apoptosis in human plaque derived vascular smooth muscle cells by Fas-ligand/Fas interactions. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1402-1407
15. Boyle J.J., Weissberg P.L., and Bennett M.R. Human macrophage-induced vascular smooth muscle cell apoptosis requires NO enhancement of Fas/Fas-L interactions. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1624-1630
16. Boyle J.J., Weissberg P.L., and Bennett M.R. Tumor necrosis factor-{alpha} promotes macrophage-induced vascular smooth muscle cell apoptosis by direct and autocrine mechanisms. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1553-1558
17. Kolodgie F.D., Narula J., Burke A.P., Haider N., Farb A., Hui-Liang Y., Smialek J., and Virmani R. Localization of apoptotic macrophages at the site of plaque rupture in sudden coronary death. Am. J. Pathol. 157 (2000) 1259-1268
18. Pryshchep S., Sato K., Goronzy J.J., and Weyand C.M. T cell recognition and killing of vascular smooth muscle cells in acute coronary syndrome. Circ. Res. 98 (2006) 1168-1176
19. Sato K., Niessner A., Kopecky S.L., Frye R.L., Goronzy J.J., and Weyand C.M. TRAIL-expressing T cells induce apoptosis of vascular smooth muscle cells in the atherosclerotic plaque. J. Exp. Med. 203 (2006) 239-250
20. Pollman M., Hall J., and Gibbons G. Acute induction of medial cell apoptosis by angioplasty injury: regulation by redox-sensitive mechanisms. Circulation 96 (1997) I-560
21. Bauriedel G., Schluckebier S., Hutter R., Welsch U., Kandolf R., Luderitz B., and Prescott M.F. Apoptosis in restenosis versus stable-angina atherosclerosis: implications for the pathogenesis of restenosis. Arterioscler. Thromb. Vasc. Biol. 18 (1998) 1132-1139
22. Pollman M.J., Hall J.L., Mann M.J., Zhang L.N., and Gibbons G.H. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat. Med. 4 (1998) 222-227
23. Kopp C.W., and de Martin R. Gene therapy approaches for the prevention of restenosis. Curr. Vasc. Pharmacol. 2 (2004) 183-189
24. Ferguson III J.E., and Patterson C. Break the cycle: the role of cell-cycle modulation in the prevention of vasculoproliferative diseases. Cell Cycle 2 (2003) 211-219
25. LopezCandales A., Holmes D.R., Liao S.X., Scott M.J., Wickline S.A., and Thompson R.W. Decreased vascular smooth muscle cell density in medial degeneration of human abdominal aortic aneurysms. Am. J. Pathol. 150 (1997) 993-1007
26. Chan W.L., Pejnovic N., Hamilton H., Liew T.V., Popadic D., Poggi A., and Khan S.M. Atherosclerotic abdominal aortic aneurysm and the interaction between autologous human plaque-derived vascular smooth muscle cells, type 1 NKT, and helper T cells. Circ. Res. 96 (2005) 675-683
27. van der Meer I.M., Oei H.H., Hofman A., Pols H.A., de Jong F.H., and Witteman J.C. Soluble Fas, a mediator of apoptosis, C-reactive protein, and coronary and extracoronary atherosclerosis The Rotterdam Coronary Calcification Study. Atherosclerosis 189 (2006) 464-469
28. Slee E.A., Harte M.T., Kluck R.M., Wolf B.B., Casiano C.A., Newmeyer D.D., Wang H.G., Reed J.C., Nicholson D.W., Alnemri E.S., Green D.R., and Martin S.J. Ordering the cytochrome c-initiated caspase cascade: hierarchical activation of caspases-2, -3, -6, -7, -8, and -10 in a caspase-9-dependent manner. J. Cell Biol. 144 (1999) 281-292
29. Chan S.-W., Hegyi L., Scott S., Cary N., Weissberg P., and Bennett M. Sensitivity to Fas-mediated apoptosis is determined below receptor level in vascular smooth muscle cells. Circ. Res. 86 (2000) 1038-1046
30. Men B.Z., Zhou D.B., Zhang X.M., and Shi H.Y. Bcl-2/Bax gene expression in different types of carotid plaque. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 27 (2005) 241-244
31. Bennett M., Macdonald K., Chan S.-W., Simari R., Luzio J., and Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 282 (1998) 290-293
32. Botto N., Rizza A., Colombo M., Mazzone A., Manfredi S., Masetti S., Clerico A., Biagini A., and Andreassi M. Evidence for DNA damage in patients with coronary artery disease. Mutat. Res. 493 (2001) 23-30
33. Andreassi M. Coronary atherosclerosis and somatic mutations: an overview of the contributive factors for oxidative DNA damage. Mutat. Res. 543 (2003) 67-86
34. Botto N., Berti S., Manfredi S., Al-Jabri A., Federici C., Clerico A., Ciofini E., Biagini A., and Andreassi M.G. Detection of mtDNA with 4977 bp deletion in blood cells and atherosclerotic lesions of patients with coronary artery disease. Mutat. Res. 570 (2005) 81-88
35. Lee J.W., Kusumoto R., Doherty K.M., Lin G.X., Zeng W., Cheng W.H., von Kobbe C., Brosh Jr. R.M., Hu J.S., and Bohr V.A. Modulation of Werner syndrome protein function by a single mutation in the conserved RecQ domain. J. Biol. Chem. 280 (2005) 39627-39636
36. Casalone R., Granata P., Minelli E., Portentoso P., Giudici A., Righi R., Castelli P., Socrate A., and Frigerio B. Cytogenetic analysis reveals clonal proliferation of smooth muscle cells in atherosclerotic plaques. Hum. Genet. 87 (1991) 139-143
37. Matturri L., Cazzullo A., Turconi P., Lavezzi A., Vandone P., Gabrielli L., Fernanez A., Grana D., and Milei J. Atherosclerosis. Chromosomal alterations in atherosclerotic plaques 15 (2001) 755-761
38. McCaffrey T.A., Du B.H., Consigli S., Szabo P., Bray P.J., Hartner L., Weksler B.B., Sanborn T.A., Bergman G., and Bush H.L. Genomic instability in the type II TGF-beta 1 receptor gene in atherosclerotic and restenotic vascular cells. J. Clin. Invest. 100 (1997) 2182-2188
39. Hatzistamou J., Kiaris H., Ergazaki M., and Spandidos D.A. Loss of heterozygosity and microsatellite instability in human atherosclerotic plaques. Biochem. Biophys. Res. Commun. 225 (1996) 186-190
40. Chung I.M., Schwartz S.M., and Murry C.E. Clonal architecture of normal and atherosclerotic aorta - implications for atherogenesis and vascular development. Am. J. Pathol. 152 (1998) 913-923
41. Ballinger S.W., Patterson C., Knight-Lozano C.A., Burow D.L., Conklin C.A., Hu Z., Reuf J., Horaist C., Lebovitz R., Hunter G.C., McIntyre K., and Runge M.S. Mitochondrial integrity and function in atherogenesis. Circulation 106 (2002) 544-549
42. Binkova B., Smerhovsky Z., Strejc P., Boubelik O., Stavkova Z., Chvatalova I., and Sram R.J. DNA-adducts and atherosclerosis: a study of accidental and sudden death males in the Czech Republic. Mutat. Res. 501 (2002) 115-128
43. Botto N., Masetti S., Petrozzi L., Vassalle C., Manfredi S., Biagini A., and Andreassi M.G. Elevated levels of oxidative DNA damage in patients with coronary artery disease. Coron. Artery Dis. 13 (2002) 269-274
44. De Flora S., Izzotti A., Walsh D., Degan P., Petrilli G.L., and Lewtas J. Molecular epidemiology of atherosclerosis. FASEB J. 11 (1997) 1021-1031
45. Martinet W., Knaapen M.W., De Meyer G.R., Herman A.G., and Kockx M.M. Elevated levels of oxidative DNA damage and DNA repair enzymes in human atherosclerotic plaques. Circulation 106 (2002) 927-932
46. Martinet W., Knaapen M., De Meyer G., Herman A., and Kockx M. Oxidative DNA damage and repair in experimental atherosclerosis are reversed by dietary lipid lowering. Circ. Res. 88 (2001) 733-739
47. Basta G., Schmidt A.M., and De Caterina R. Advanced glycation end products and vascular inflammation: implications for accelerated atherosclerosis in diabetes. Cardiovasc. Res. 63 (2004) 582-592
48. Bucala R., Makita Z., Koschinsky T., Cerami A., and Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 6434-6438
49. Williams G.M., and Jeffrey A.M. Oxidative DNA damage: endogenous and chemically induced. Regul. Toxicol. Pharmacol. 32 (2000) 283-292
50. Mohazzab K.M., Kaminski P.M., and Wolin M.S. NADH oxidoreductase is a major source of superoxide anion in bovine coronary artery endothelium. Am. J. Physiol. 266 (1994) H2568-H2572
51. Griendling K.K., Minieri C.A., Ollerenshaw J.D., and Alexander R.W. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ. Res. 74 (1994) 1141-1148
52. Wassmann S., Wassmann K., and Nickenig G. Modulation of oxidant and antioxidant enzyme expression and function in vascular cells. Hypertension 44 (2004) 381-386
53. Michalik V., Spotheim Maurizot M., and Charlier M. Calculation of hydroxyl radical attack on different forms of DNA. J. Biomol. Struct. Dyn. 13 (1995) 565-575
54. Offord E., van Poppel G., and Tyrrell R. Markers of oxidative damage and antioxidant protection: current status and relevance to disease. Free Radic. Res. 33 Suppl (2000) S5-S19
55. Warnholtz A., Nickenig G., Schulz E., Macharzina R., Brasen J.H., Skatchkov M., Heitzer T., Stasch J.P., Griendling K.K., Harrison D.G., Bohm M., Meinertz T., and Munzel T. Increased NADH-oxidase-mediated superoxide production in the early stages of atherosclerosis: evidence for involvement of the renin-angiotensin system. Circulation 99 (1999) 2027-2033
56. Sorescu D., Weiss D., Lassegue B., Clempus R.E., Szocs K., Sorescu G.P., Valppu L., Quinn M.T., Lambeth J.D., Vega J.D., Taylor W.R., and Griendling K.K. Superoxide production and expression of nox family proteins in human atherosclerosis. Circulation 105 (2002) 1429-1435
57. Barry-Lane P.A., Patterson C., van der Merwe M., Hu Z., Holland S.M., Yeh E.T., and Runge M.S. p47phox is required for atherosclerotic lesion progression in ApoE(-/-) mice. J. Clin. Invest. 108 (2001) 1513-1522
58. Landmesser U., Merten R., Spiekermann S., Buttner K., Drexler H., and Hornig B. Vascular extracellular superoxide dismutase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation 101 (2000) 2264-2270
59. Blankenberg S., Rupprecht H.J., Bickel C., Torzewski M., Hafner G., Tiret L., Smieja M., Cambien F., Meyer J., and Lackner K.J. Glutathione peroxidase 1 activity and cardiovascular events in patients with coronary artery disease. N. Engl. J. Med. 349 (2003) 1605-1613
60. Ballinger S., Patterson C., Yan C., Doan R., Burow D., Young C., Yakes F., van Houten B., Ballinger C., Freeman B., and Runge M. Hydrogen peroxide and peroxynitrite induced mitochondrial DNA damage and dysfunction in vascular endothelial and smooth muscle cells. Circ. Res. 86 (2000) 960-966
61. Makover D., Cuddy M., Yum S., Bradley K., Alpers J., Sukhatme V., and Reed J.C. Phorbol ester-mediated inhibition of growth and regulation of proto-oncogene expression in the human T cell leukemia line JURKAT. Oncogene 6 (1991) 455-460
62. d'Adda di Fagagna F., Teo S., and Jackson S. Functional links between telomeres and proteins of the DNA-damage response. Genes Dev. 18 (2004) 1781-1799
63. Banin S., Moyal L., Shieh S., Taya Y., Anderson C., Chessa L., Smorodinsky N., Prives C., Shiloh R.Y.Y., and Ziv Y. Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281 (1998) 1674-1677
64. Canman C., Lim D., Cimprich K., Taya Y., Tamai K., Sakaguchi K., Appella E., Kastan M., and Siliciano J. Activation of the ATM kinase by ionising radiation and phosphorylation of p53. Science 281 (1998) 1677-1679
65. Khanna K., Keating K., Kozlov S., Scott S., Gatei M., Hobson K., Taya Y., Gabrielli B., Chan D., Lees-Miller S., and Lavin M. ATM associates with and phosphorylates p53: mapping the region of interaction. Nat. Genet. 20 (1998) 398-400
66. Hammond E., Denko N., Dorie M., Abraham R., and Giaccia A. Hypoxia links ATR and p53 through replication arrest. Mol. Cell. Biol. 22 (2002) 1834-1843
67. Dumaz N., and MeeK D. Serine 15 phosphorylation stimulates p53 transactivation but does not directly influence interaction with HDM2. EMBO J. 18 (1999) 7002-7010
68. Bartek J., Falck J., and Lukas J. ChK2 kinase: a busy messenger. Nat. Rev. Mol. Biol. 2 (2001) 877-886
69. McGowan C. Checking in on Cds1 (ChK2): a checkpoint kinase and tumor suppressor. BioEssays 24 (2002) 502-511
70. Oren M., Damalas A., Gottlieb T., Michael D., Taplick J., Leal J., Maya R., Moas M., Seger R., Taya Y., and Benzeev A. Regulation of p53: intricate loops and delicate balances. Ann. N.Y. Acad. Sci. 973 (2000) 374-383
71. Maya R., Balass M., Kim S., Shkedy D., Leal J., Shifman O., Moas M., Buschmann T., Ronai Z., Shiloh Y., Kastan M., katzir F., and Oren M. ATM-dependent phosphorylation of Mdm2 on serine 395: role in p53 activation by DNA damage. Genes Dev. 15 (2001) 1067-1077
72. Stenger E., Mayr G., Mann K., and Tegtmeyer P. Formation of stable p53 homotetramers and multiples of tetramers. Mol. Carcinog. 5 (1992) 102-106
73. Vousden K., and Lu X. Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002) 594-604
74. Yonish-Rouach E., Deguin V., Zaitchouk T., Breugnot C., Mishal Z., Jenkins J., and May E. Transcriptional activation plays a role in the induction of apoptosis by transiently transfected wild-type p53. Oncogene 12 (1996) 2197-2205
75. Donatella Attardi L., Lowe S., Brugarolas J., and Jacks T. Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. EMBO J. 15 (1996) 3693-3701
76. Sabbatini P., Han J., Chiou S.K., Nicholson D.W., and White E. Interleukin 1 beta converting enzyme-like proteases are essential for p53-mediated transcriptionally dependent apoptosis. Cell Growth Differ. 8 (1997) 643-653
77. Caelles C., Helmberg A., and Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370 (1994) 220-223
78. waf1/cip1. Genes Dev. 8 (1994) 2817-2830
79. Schuler M., Bossy-Wetzel E., Goldstein J.C., Fitzgerald P., and Green D.R. p53 induces apoptosis by caspase activation through mitochondrial cytochrome c release. J. Biol. Chem. 275 (2000) 7337-7342
80. Marchenko N.D., Zaika A., and Moll U.M. Death signal-induced localization of p53 protein to mitochondria. A potential role in apoptotic signalling. J. Biol. Chem. 275 (2000) 16202-16212
81. Muller M., Strand S., Hug H., Heinemann E.M., Walczak H., Hofmann W.J., Stremmel W., Krammer P.H., and Galle P.R. Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild- type p53. J. Clin. Invest. 99 (1997) 403-413
82. Aragane Y., Kulms D., Metze D., Wilkes G., Poppelmann B., Luger T.A., and Schwarz T. Ultraviolet light induces apoptosis via direct activation of CD95 (Fas/APO-1) independently of its ligand CD95L. J. Cell Biol. 140 (1998) 171-182
83. Sheikh M.S., Burns T.F., Huang Y., Wu G.S., Amundson S., Brooks K.S., Fornace A.J., and ElDeiry W.S. p53-dependent and -independent regulation of the death receptor KILLER/DR5 gene expression in response to genotoxic stress and tumor necrosis factor alpha. Cancer Res. 58 (1998) 1593-1598
84. Sayan B.S., Sayan A.E., Knight R.A., Melino G., and Cohen G.M. p53 is cleaved by caspases generating fragments localizing to mitochondria. J. Biol. Chem. 281 (2006) 13566-13573
85. Tinel A., and Tschopp J. The PIDDosome, a protein complex implicated in activation of caspase-2 in response to genotoxic stress. Science 304 (2004) 843-846
86. Vakifahmetoglu H., Olsson M., Orrenius S., and Zhivotovsky B. Functional connection between p53 and caspase-2 is essential for apoptosis induced by DNA damage. Oncogene 25 (2006) 5683-5692
87. Ihling C., Haendeler J., Menzel G., Hess R.D., Fraedrich G., Schaefer H.E., and Zeiher A.M. Co-expression of p53 and MDM2 in human atherosclerosis: implications for the regulation of cellularity of atherosclerotic lesions. J. Pathol. 185 (1998) 303-312
88. Ihling C., Menzel G., Wellens E., Monting J.S., Schaefer H.E., and Zeiher A.M. Topographical association between the cyclin-dependent kinases inhibitor p21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. Arterioscler. Thromb. Vasc. Biol. 17 (1997) 2218-2224
89. Scheinman M., Ascher E., Levi G.S., Hingorani A., Shirazian D., and Seth P. p53 gene transfer to the injured rat carotid artery decreases neointimal formation. J. Vasc. Surg. 29 (1999) 360-369
90. George S.J., Angelini G.D., Capogrossi M.C., and Baker A.H. Wild-type p53 gene transfer inhibits neointima formation in human saphenous vein by modulation of smooth muscle cell migration and induction of apoptosis. Gene Ther. 8 (2001) 668-676
91. Matsushita H., Morishita R., Aoki M., Tomita N., Taniyama Y., Nakagami H., Shimozato T., Higaki J., Kaneda Y., and Ogihara T. Transfection of antisense p53 tumor suppressor gene oligodeoxynucleotides into rat carotid artery results in abnormal growth of vascular smooth muscle cells. Circulation 101 (2000) 1447-1452
92. Li Z.H., and Lakatta E.G. Localized apoptosis and enhanced expression of p53 and interleukin-1 beta converting enzyme (ICE) proteins in human aortic atherosclerotic lesions. Atherosclerosis 134 (1997) 299
93. Hayashi S., Morishita R., Higaki J., Tomita N., and Ogihara T. Inhibition of growth of human aortic vascular smooth muscle cells by a phosphodiesterase type 3 inhibitor, cilostazol, through p53- mediated apoptosis. Atherosclerosis 134 (1997) 257
94. Kinscherf R., Claus R., Wagner M., Gehrke C., Kamencic H., Hou D., Nauen O., Schmiedt W., Kovacs G., Pill J., Metz J., and Deigner H.P. Apoptosis caused by oxidized LDL is manganese superoxide dismutase and p53 dependent. FASEB J. 12 (1998) 461-467
95. Guevara N., Kim H.-S., Antonova E., and Chan L. The absence of p53 accelerates atherosclerosis by increasing cell proliferation in vivo. Nat. Med. 5 (1999) 335-339
96. van Vlijmen B.J., Gerritsen G., Franken A.L., Boesten L.S., Kockx M.M., Gijbels M.J., Vierboom M.P., van Eck M., van De Water B., van Berkel T.J., and Havekes L.M. Macrophage p53 deficiency leads to enhanced atherosclerosis in APOE*3-Leiden transgenic mice. Circ. Res. 88 (2001) 780-786
97. Merched A.J., Williams E., and Chan L. Macrophage-specific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler. Thromb. Vasc. Biol. 23 (2003) 1608-1614
98. Mercer J., Figg N., Stoneman V., Braganza D., and Bennett M.R. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ. Res. 96 (2005) 667-674